Current achievements in the production of complex biopharmaceuticals with moss bioreactors.

Current achievements in the production of complex biopharmaceuticals with moss bioreactors. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Current achievements in the production of complex biopharmaceuticals with moss bioreactors. Abstract Text:

Eva L Decker,Ralf Reski,

Transgenic plants are promising alternatives for the low-cost and safe pathogen-free production of complex recombinant pharmaceutical proteins (molecular farming). Plants as higher eukaryotes perform posttranslational modifications similar to those of mammalian cells. However, plant-specific protein N-glycosylation was shown to be immunogenic, a fact that represents a drawback for many plant systems in biopharmaceutical production. The moss Physcomitrella patens offers unique properties as a contained system for protein production. It is grown in the predominant haploid gametophytic stage as tissue suspension cultures in photobioreactors. Efficient secretory signals and a transient transfection system allow the secretion of freshly synthesized proteins to the surrounding medium. The key advantage of Physcomitrella compared to other plant systems is the feasibility of targeted gene replacements. By this means, moss strains with non-immunogenic humanized glycan patterns were created. Here we present an overview of the relevant aspects for establishing moss as a production system for recombinant biopharmaceuticals.

Current achievements in the production of complex biopharmaceuticals with moss bioreactors. Publishing Authors By Initials

EL Decker,R Reski,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Current achievements in the production of complex biopharmaceuticals with moss bioreactors. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Bioprocess and biosystems engineering

VOLUME: 31

Page Numbers: 3-9

Journal Abbreviation:

ISSN: 1615-7591

DAY: 14

MONTH: 08

YEAR: 2007

Current achievements in the production of complex biopharmaceuticals with moss bioreactors. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101088505

Current achievements in the production of complex biopharmaceuticals with moss bioreactors. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Current achievements in the production of complex biopharmaceuticals with moss bioreactors. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Current achievements in the production of complex biopharmaceuticals with moss bioreactors.

AFFILIATION: Plant Biotechnology, Faculty of Biology, Freiburg University, Schaenzlestr. 1, 79104, Freiburg, Germany, eva.decker@biologie.uni-freiburg.de.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Bioprocess Biosyst Eng

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Current achievements in the production of complex biopharmaceuticals with moss bioreactors Related Publications

• A mitochondrial protein homologous to the mammalian peripheral-type benzodiazepine receptor is essential for stress adaptation in plants.
• An integrated physiological and genetic approach to the dynamics of FtsZ targeting and organisation in a moss, Physcomitrella patens.
• Current achievements in the production of complex biopharmaceuticals with moss bioreactors.
• Do we need another model plant?
• High throughput cryopreservation of 140,000 Physcomitrella patens mutants.
• Large-scale analysis of 73 329 physcomitrella plants transformed with different gene disruption libraries: production parameters and mutant phenotypes.
• Molecular tools to study Physcomitrella patens.
• Moss bioreactors producing improved biopharmaceuticals.
• Plant proteomics.